Epitalon, a lab-made four-amino-acid peptide modeled on a cattle brain-gland extract, is injected in short courses hoping to slow cell aging, restore nighttime melatonin (the sleep hormone) and extend healthy life. Lab and animal results are striking; human evidence is thin, almost entirely from its developers. The main risk is theoretical but serious for this audience: possibly helping hidden cancer cells survive. A low-cost, plausible but largely unproven add-on. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Complete blood count (CBC) with differential | White cells 5.0–8.0 ×10⁹/L; hemoglobin 13.5–15.5 g/dL (women), 14.0–16.5 g/dL (men) | Screens for blood disorders and hidden cancer |
| Liver enzymes (alanine and aspartate aminotransferase) | 10–26 U/L | Detects liver injury from contaminated products |
| eGFR (estimated glomerular filtration rate) and creatinine | eGFR above 90 mL/min/1.73 m² | Confirms kidney clearance |
| Fasting glucose and HbA1c (3-month average blood sugar) | Glucose 75–90 mg/dL; HbA1c 4.8–5.3% | Tracks possible glucose-lowering effect |
| hs-CRP (high-sensitivity C-reactive protein) | Below 1.0 mg/L | General inflammation marker |
| Urinary aMT6s (6-sulfatoxymelatonin), overnight | No established target; track change from own baseline | Measures nighttime melatonin output |
| Telomere length | No established target; track change from own baseline | Tests the claimed telomere effect |
| PSA (prostate-specific antigen, men) | Below 1.0 ng/mL under age 60; stable over time | Prostate cancer screening |
Cadence: Baseline before the first course, with age-appropriate cancer screening up to date within 12 months; blood panel repeated about 2–4 weeks after each course, then every 6–12 months while courses continue; optional telomere and melatonin tests repeated only with the same laboratory and method; any new lump, weight loss or bleeding prompts earlier evaluation.